Form 4: Phio Pharmaceuticals CEO Robert Bitterman Increases Stake in Company
SEC Form 4
Robert Bitterman, President & CEO of Phio Pharmaceuticals Corp., recently purchased 2,500 shares of common stock at $0.91 per share, increasing his total holdings.
Summary
- On February 26, 2024, Robert J Bitterman, the President & CEO and a Director of Phio Pharmaceuticals Corp., acquired 2,500 shares of common stock.
- The purchase price was $0.91 per share.
- Following the transaction, Bitterman directly owns 18,990 shares of Phio Pharmaceuticals Corp.
- This includes shares of common stock underlying unvested restricted stock units.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase suggests confidence, but it's a relatively small transaction.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's just one factor to consider when evaluating a company's potential.
Stakeholder Impact
- The CEO's increased stake could be viewed positively by shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date of transaction: Robert Bitterman purchased 2,500 shares of Phio Pharmaceuticals Corp. |
| 02/27/2024 | Date of signature on the Form 4 filing. |
Keywords
Phio Pharmaceuticals, Robert Bitterman, insider trading, stock purchase, Form 4, PHIO, CEO, ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.